Condition
Oligoprogression clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Oligoprogression clinical trials that are recruiting, at sites in 4 countries (most in Canada (2), Ireland (1), France (1)). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 4Countries
Newest Oligoprogression clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Stereotactic body radiotherapy (SABR) for limited metastases | — | Seoul | Recruiting | Aug 13, 2025 |
| Stereotactic ablative radiotherapy versus single‑fraction palliative radiotherapy for oligoprogressive metastatic cancer | — | Surrey, British Columbia | Recruiting | Apr 9, 2025 |
| Comparing single and multiple doses of radiation therapy for treating oligometastatic disease | — | Kelowna, British Columbia and 13 other locations | Recruiting | Mar 24, 2023 |
| Hypofractionated (3×10 Gy) versus single‑dose (20–25 Gy) stereotactic radiotherapy for limited brain metastases | — | Bordeaux and 14 other locations | Recruiting | Nov 1, 2021 |
All recruiting trials (4)
-
Stereotactic body radiotherapy (SABR) for limited metastases
This program tries stereotactic body radiotherapy (SABR) in people with up to five oligometastatic or oligoprogressive cancer lesions to see if it controls disease better, affects symptoms and side effects, and changes ctDNA in the blood.
-
Stereotactic ablative radiotherapy versus single‑fraction palliative radiotherapy for oligoprogressive metastatic cancer
This trial will test whether stereotactic ablative radiotherapy (SABR) works better than single‑fraction palliative radiotherapy (8 Gy) for people with 1–5 oligoprogressive metastatic lesions to delay the need for next‑line systemic therapy and improve quality of life.
-
Comparing single and multiple doses of radiation therapy for treating oligometastatic disease
This study is testing whether one dose or several doses of radiation therapy works better and is safer for people with oligometastatic disease, while also looking at how it affects their quality of life and costs.
-
Hypofractionated (3×10 Gy) versus single‑dose (20–25 Gy) stereotactic radiotherapy for limited brain metastases
This trial will try whether giving stereotactic radiotherapy in three 10 Gy sessions works as well or better than the traditional single high‑dose (20–25 Gy) radiosurgery for adults with up to five small brain metastases.
Related topics
Quick answers
How many Oligoprogression clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in Canada (2 trials), Ireland (1 trial), France (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.